Amicus Therapeutics Inc to Discuss the Preclinical Data Presented at ASGCT - Call Transcript
Good day, ladies and gentlemen, and welcome to the Amicus Therapeutics Positive Preclinical Gene Therapy Data Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to Sara Pellegrino, Vice President of Investor Relations and Corporate Communications. Ma'am, you may begin.
Thank you, Shannon. Good morning, and welcome everyone to our conference call to discuss Amicus Therapeutics positive preclinical Pompe disease gene therapy data. Speaking on today's call we have John Crowley, Chairman and Chief Executive Officer; and Dr. Hung Do, Chief Science Officer. Also available to participate in the Q&A, we have Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; Jay Barth; Chief Medical Officer; and Jeff Castelli, Chief Portfolio Officer and Head of Gene therapy.
On this call, as referenced on Slide 2, we may make forward-looking statements within the meaning of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |